Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Holding TVTX?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.58Last Year’s EPS
-1.18Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -3.89%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Travere Therapeutics, with significant advancements in the approval and market expansion of FILSPARI, strong financial growth, and promising regulatory progress for FSGS. However, challenges remain with the pause in pegtibatinase enrollment and reported net loss.Company Guidance
During the third quarter 2024 earnings call for Travere Therapeutics, the company reported robust financial and strategic advancements. Notably, there was a significant 30% quarter-over-quarter increase in net sales for FILSPARI, driven by strong demand and new patient start forms. The company achieved $35.6 million in net product sales of FILSPARI, contributing to a total revenue of $62.9 million, which reflects an 80% increase compared to the same period in 2023. Furthermore, Travere highlighted the successful launch in Europe and the strategic filing of an sNDA for modifying liver monitoring frequency for FILSPARI. The company also discussed their engagement with the FDA regarding the potential sNDA submission for sparsentan in FSGS, anticipating a path to full approval next year. Overall, the financial results and strategic initiatives underscore Travere's commitment to expanding their leadership in rare kidney diseases.FILSPARI Approval and Market Expansion
FILSPARI received full approval for IgA nephropathy, leading to significant growth in net sales by more than 30% over the last quarter. The product's new label supports broader use in patients at risk of progression and has been launched in key European markets.
Strong Financial Performance
Net product sales for the third quarter of 2024 grew to $61 million, an increase of approximately 80% compared to the same period in 2023, driven by the ongoing U.S. launch of FILSPARI.
Positive Clinical Data and Regulatory Progress
New clinical data presented at ASN Kidney Week supports the efficacy of FILSPARI in reducing proteinuria and preserving kidney function. Additionally, an sNDA was submitted to modify liver monitoring frequency, potentially improving patient access.
PARASOL Initiative and FSGS Opportunity
Recommendations from the PARASOL group support a proteinuria-based endpoint for FSGS trials. Travere is preparing for a meeting with the FDA regarding an sNDA submission for sparsentan in FSGS.
Reduced Operating Expenses
Research and development expenses decreased from $60.6 million in Q3 2023 to $51.7 million in Q3 2024, reflecting restructuring efforts and reduced clinical expenses.
---
TVTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TVTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $17.76 | $17.50 | -1.46% |
| Aug 01, 2024 | $9.24 | $9.00 | -2.60% |
| May 06, 2024 | $6.55 | $6.75 | +3.05% |
| Feb 15, 2024 | $8.74 | $8.20 | -6.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Travere Therapeutics (TVTX) report earnings?
Travere Therapeutics (TVTX) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Travere Therapeutics (TVTX) earnings time?
Travere Therapeutics (TVTX) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TVTX EPS forecast?
TVTX EPS forecast for the fiscal quarter 2024 (Q4) is -0.58.
---